About Edesa Biotech
Addressing Unmet Medical Needs
Late-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for inflammatory and immune-related diseases
Beyond Steroids
Edesa Biotech is a clinical-stage biopharmaceutical company founded by experts in inflammatory and autoimmune diseases. We are exploring new ways to treat diseases, including alternatives to steroids and JAK inhibitors, which can have serious side-effects.
We prioritize our efforts on disease indications where there is compelling scientific rationale and where there are significant unmet medical needs, among other factors. We have multiple late-stage product candidates in our development pipeline in the fields of respiratory diseases and medical dermatology, including:
Vitiligo, an autoimmune disorder that causes the skin to lose its color in patches.
Allergic Contact Dermatitis, a common work-related skin condition.
Acute Respiratory Distress Syndrome, a life-threatening form of respiratory failure; and
Pulmonary Fibrosis, a progressive lung disease that causes lung scarring and shortness of breath.
At the heart of Edesa’s corporate culture is an entrepreneurial spirit, and we are always building. See our latest news releases for updates on these clinical programs and more.
– Par Nijhawan, MD, Chief Executive Officer
Edesa's Leadership
Our leadership has years of specialized expertise spanning pharmaceutical drug development, biotech research and medical care.
Executive Offices
U.S. Offices
Online Contact Form
Headquarters
Our executive offices are located in the Greater Toronto Area
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario L3R 5H6
+1 289.800.9600
Edesa Careers
Join us in the discovery and development of a new generation of pharmaceutical drugs